JP2023507115A5 - - Google Patents

Info

Publication number
JP2023507115A5
JP2023507115A5 JP2022536572A JP2022536572A JP2023507115A5 JP 2023507115 A5 JP2023507115 A5 JP 2023507115A5 JP 2022536572 A JP2022536572 A JP 2022536572A JP 2022536572 A JP2022536572 A JP 2022536572A JP 2023507115 A5 JP2023507115 A5 JP 2023507115A5
Authority
JP
Japan
Prior art keywords
human
disease
juvenile
chimeric molecule
arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022536572A
Other languages
English (en)
Japanese (ja)
Other versions
JP7755581B2 (ja
JP2023507115A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065734 external-priority patent/WO2021127262A1/en
Publication of JP2023507115A publication Critical patent/JP2023507115A/ja
Publication of JP2023507115A5 publication Critical patent/JP2023507115A5/ja
Application granted granted Critical
Publication of JP7755581B2 publication Critical patent/JP7755581B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022536572A 2019-12-17 2020-12-17 治療における使用のためのデュアルインターロイキン-2/tnf受容体アゴニスト Active JP7755581B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949380P 2019-12-17 2019-12-17
US62/949,380 2019-12-17
PCT/US2020/065734 WO2021127262A1 (en) 2019-12-17 2020-12-17 Dual interleukin-2 /tnf receptor agonist for use in therapy

Publications (3)

Publication Number Publication Date
JP2023507115A JP2023507115A (ja) 2023-02-21
JP2023507115A5 true JP2023507115A5 (cg-RX-API-DMAC7.html) 2023-12-19
JP7755581B2 JP7755581B2 (ja) 2025-10-16

Family

ID=74191856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022536572A Active JP7755581B2 (ja) 2019-12-17 2020-12-17 治療における使用のためのデュアルインターロイキン-2/tnf受容体アゴニスト

Country Status (17)

Country Link
US (1) US20230040604A1 (cg-RX-API-DMAC7.html)
EP (1) EP4077383A1 (cg-RX-API-DMAC7.html)
JP (1) JP7755581B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220114595A (cg-RX-API-DMAC7.html)
CN (1) CN114867749A (cg-RX-API-DMAC7.html)
AU (1) AU2020407208A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011949A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162705A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001638A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022008768A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220341A (cg-RX-API-DMAC7.html)
IL (1) IL293471A (cg-RX-API-DMAC7.html)
JO (1) JOP20220151A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022007712A (cg-RX-API-DMAC7.html)
PE (1) PE20221506A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551428A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021127262A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114555634B (zh) 2019-08-13 2025-01-10 美国安进公司 用于扩增调节性t细胞的白介素-2突变蛋白
WO2026006809A1 (en) * 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447A (en) 1846-04-04 Car- wheel
US233A (en) 1837-06-14 Improvement in plows
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
BR9908226A (pt) * 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
AU762382B2 (en) 1998-09-29 2003-06-26 Pioneer Hi-Bred International, Inc. MAR/SAR elements flanking RSYN7-driven construct
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
US7259010B2 (en) 2000-12-15 2007-08-21 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region of interferon beta
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
ES2295639T3 (es) 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
KR20070003934A (ko) 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
BRPI0607351A2 (pt) 2005-02-15 2009-09-01 Novartis Vaccines & Diagnostic métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20
CA2597584A1 (en) * 2005-02-15 2006-08-24 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類cd134(ox40)之人類單株抗體及其製造及使用方法
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Il−2媒介性免疫応答の有効性を高める組成物および方法
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010085495A1 (en) 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
AU2010216152B2 (en) 2009-02-17 2015-05-14 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
WO2011106707A2 (en) 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
LT2609118T (lt) * 2010-08-23 2017-04-25 Board Of Regents, The University Of Texas System Anti-ox40 antikūnai ir jų panaudojimo būdai
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
KR102119840B1 (ko) 2011-07-11 2020-06-09 아이크노스 사이언스 에스. 아. Ox40에 결합하는 항체 및 이들의 용도
JP6038920B2 (ja) 2011-08-23 2016-12-07 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 抗ox40抗体およびそれを使用する方法
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
RS57840B1 (sr) 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
SG11201607969XA (en) 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
AU2015242752A1 (en) 2014-04-04 2016-10-20 Kyowa Hakko Kirin Co., Ltd. Anti-death receptor 3 (DR3) antagonistic antibodies with reduced agonistic activity
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
CN106456734A (zh) * 2014-05-29 2017-02-22 免疫医疗有限责任公司 Ox40l融合蛋白及其用途
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗-ox40抗體及其用途
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
AU2016271111B2 (en) * 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
US11053293B2 (en) * 2016-02-05 2021-07-06 Washington University Compositions and methods for targeted cytokine delivery
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
UY37523A (es) 2016-12-15 2018-07-31 Abbvie Biotherapeutics Inc Anticuerpos anti-ox40 y sus usos
US11407806B2 (en) * 2017-04-06 2022-08-09 Albert Einstein College Of Medicine Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells
MX2020007291A (es) * 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
JP7534215B2 (ja) * 2018-01-24 2024-08-14 ベイジン パーカンズ オンコロジー カンパニー リミテッド サイトカイン融合タンパク質
CN108285490A (zh) * 2018-01-26 2018-07-17 西南交通大学 一种高亲和性结合i型胶原蛋白的gst融合蛋白制备及其应用
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof

Similar Documents

Publication Publication Date Title
KR102036399B1 (ko) 단백질 발현용 재조합 박테리아 숙주 세포
JP2016518823A5 (cg-RX-API-DMAC7.html)
WO2010055366A4 (en) Anti-human il-21 monoclonal antibodies
US20080227704A1 (en) CXCL13 binding proteins
EP2598516B1 (en) Process for purifying proteins
EP3342783B1 (en) Method for controlling affinity of antibody for antigen, antibody whose affinity for antigen has been altered, and its production method
CN117043184A (zh) 抗人血清白蛋白(hsa)的纳米抗体及其应用
JP7785820B2 (ja) 抗体精製
CN108178799B (zh) 一种抗ca125糖类抗原的纳米抗体及其应用
CN113831411B (zh) 针对l1cam的单域抗体及其衍生蛋白和应用
AU2022271707A1 (en) Chimeric antigen receptors and modified cells comprising the same
CN121950879A (zh) 用于防止正亮氨酸错误地掺入蛋白质中的方法和组合物
CN116162160B (zh) 一种抗il-6的单域抗体及其用途
JP2022060392A (ja) 抗体の抗原に対する親和性を制御する方法、抗原に対する親和性が改変された抗体及びその製造方法
CN116554331B (zh) 一种抗人cd15工程抗体及应用
WO2023231888A1 (zh) 抗人生长激素单域抗体及其应用
WO2013129454A1 (ja) 新規抗ヒトil-23受容体抗体
WO2025131127A1 (zh) 抗cd5单域抗体及其应用
CN107532171A (zh) 用于生产重组同种异型特异性兔单克隆抗体的方法
CN117820481B (zh) 新型抗体分子及其制药用途
CN118126170B (zh) 一种丁酸梭菌细胞表面蛋白的抗体
Howard et al. High-level expression of recombinant Fc chimeric proteins in suspension cultures of stably transfected J558L cells
CN121293340A (zh) 普拉梭菌细菌表面蛋白的单克隆抗体及其应用
HK40110413A (en) Humanized anti-dnam-1 antibody
CN116253793A (zh) 一种纳米抗体及其制备方法和应用